Table 1.
Study/risk group | 5-y EFS, % ± SE (no.) |
|
---|---|---|
MRD− | MRD+ (> .01%)* | |
9904/SR | 95 ± 1 (668) | 64 ± 7 (105) |
9905/SR | 89 ± 2 (464) | 59 ± 6 (119) |
9905/HR | 79 ± 4 (295) | 33 ± 8 (74) |
9906/HR† | 72 ± 5 (161) | 34 ± 8 (85) |
P < .001 for all comparisons.
Also includes CNS3 patients, patients with testicular disease, or patients with MLL rearrangements.